I think this is a good report, not an update, but I am beginning to think there is really not a lot to update at this point in time. I would like to know when they expect to sell the crème on a non-prescription retail level although I believe they are working on getting that started in Europe.

As to the personnel mix ups, I hope that is not an indication of the thought that went into the critical path analysis.

Anyway, prospective investors coming across this report would likely view the Company as a serious player worthy of investment.